Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. - Test2 - elhamkhani - TriplyDB

Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.

Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.

http://www.wikidata.org/entity/Q32064655

about

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method Summary of information on human CYP enzymes: human P450 metabolism data.Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19 Coprescription of tamoxifen and medications that inhibit CYP2D6.Optimizing QSAR models for predicting ligand binding to the drug-metabolizing cytochrome P450 isoenzyme CYP2D6.Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.Interactions between recreational drugs and antiretroviral agents.Anticonvulsant and antiretroviral interactions.PharmGKB summary: Efavirenz pathway, pharmacokinetics P glycoprotein in human immunodeficiency virus type 1 infection and therapy.Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers.Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers.Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.Current status of antiretroviral therapy.Extracting drug-enzyme relation from literature as evidence for drug drug interaction Quantitative histological assessment of xenobiotic-induced liver enzyme induction and pituitary-thyroid axis stimulation in rats using whole-slide automated image analysis.Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.Drug interactions in the management of HIV infection: an update.Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Warfarin-antiretroviral interactions.Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.Drug interactions with antiretrovirals and warfarin.Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.Acute Care Management of the HIV-Infected Patient: A Report from the HIV Practice and Research Network of the American College of Clinical Pharmacy.The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism.Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.Cortisol serum levels and their relationship to certain antiretroviral drugs.

P2860

Q24628212-63816D5D-73DB-432D-9FCF-D637BFFAD7C5 Q27692040-DBBE6D26-C8DC-4432-9AB6-3BA381DCC556 Q28542714-66EFFB8E-3E3F-451F-9C11-D55A789C0CB2 Q28550189-C4A724E5-66CE-4375-AB15-358E4ED97E92 Q32103802-DE0EEE41-D9B9-4829-9BEA-353E1D505E32 Q33186873-472D70D6-9E8E-4E63-A07E-3B7BA6604A24 Q33797986-52824EE3-2CAD-40DA-BE97-EF4C8A45AD0D Q33821729-879F3306-8729-4B36-8878-2FF3A5AAFEA1 Q33898184-43377D27-87D8-4631-A110-053FD8D5FF49 Q33901341-D668350F-299A-4FCC-83F6-85432A4DD909 Q34430456-6BDC85F4-70B3-4E47-9DF5-C75198BA5232 Q34721793-0EF18CD4-CE4F-495E-A777-00A1E145BB08 Q34874414-3E6D470F-5DF7-4678-B1F1-25688D0039FE Q35670044-7BCAE4BC-DE12-4F4B-B63F-ABE7DE257303 Q35706069-48210D2E-C9A5-4C9B-AACD-389A4EF58DDD Q35718765-39389474-9835-4CF8-B3FF-1863276FBD9B Q35825158-12DC3190-9CB2-40BB-B3FD-662CBBA67CE9 Q36080621-5E34EF5C-EFE2-4076-AAAA-0A3E46AD40F6 Q36290691-EB4A6575-DCD6-455D-B31F-4D3F67EAC49F Q36362462-C3F3AF02-9A8A-42EE-B3B9-78FC2B04CD30 Q36544977-C45357A0-4CAE-42BF-85BB-D5D857E14556 Q36548703-EAB40D4D-5550-4784-AD44-307D98DAE3CB Q36657508-B915927C-704C-418A-9449-8AA057C0FF43 Q36796304-6D52D934-F2EE-4BBA-BE31-3D8513E76FC3 Q36887128-0AC790C6-945E-404D-9A82-C1028E52AE95 Q37000733-78D3348D-AC4E-4CD4-87E8-16602568967C Q37086418-BF516074-04C3-4BB9-8487-72E8927513AD Q37364219-EA7DF445-9138-415E-8C21-97BB9BEEB00A Q37378110-D3F602BB-B85F-409B-A489-CE0768063C32 Q37386503-4D3BDA9E-B76D-4B38-918E-A6561FD709E3 Q37395532-5FBCAD4D-A703-4451-AE8D-3DB3175FD2F5 Q37598731-884D3635-0935-4D8F-B110-DFBC1CF5FE52 Q37669678-87E69D65-1584-4C6C-950F-C7E8FA8D821E Q37679935-AEAE233A-4F00-4985-8890-94DD23F9A8BA Q37848142-4B622869-029B-4C6E-92A0-BA6CE45372CA Q38920747-EB97B246-284D-4F43-B61A-22BF61558DE3 Q42057303-B914FC16-589A-471F-A5C0-737F6D71F776 Q42283777-3C6E1D78-27D7-495B-976A-51502822989B Q43851688-E249BAD2-9F24-47AD-A94F-6A90704AC146 Q45015735-DE7A7489-35B9-4A8B-A02F-1584F441C887

P2860

Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.

http://www.wikidata.org/entity/Q32064655

description

2001 nî lūn-bûn

@nan

2001 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Inhibition of human cytochrome ...... erse transcriptase inhibitors.

@ast

Inhibition of human cytochrome ...... erse transcriptase inhibitors.

@en

type

label

Inhibition of human cytochrome ...... erse transcriptase inhibitors.

@ast

Inhibition of human cytochrome ...... erse transcriptase inhibitors.

@en

prefLabel

Inhibition of human cytochrome ...... erse transcriptase inhibitors.

@ast

Inhibition of human cytochrome ...... erse transcriptase inhibitors.

@en

P1433

Q32064655-F0D744BD-5DEF-42DC-9ED4-6D0E48330C38

P1476

Q32064655-F5A334C2-2D17-4350-A32D-336989DD959A

P2093

Q32064655-0E55E8E9-FAFF-4087-B74C-CE56DEB031FE

Q32064655-4ABAEEB6-2269-449D-AC74-065807BCF6BD

Q32064655-5642106C-5D09-4E56-A83F-3F745B1AE703

Q32064655-7120D087-77C2-4858-82EA-D142B35E5C54

Q32064655-84E75F6E-DD98-44F1-991D-B8E062C1407C

Q32064655-8D5F481F-23A0-4AA7-8532-66C7EF64F38F

Q32064655-CED4F964-945F-4F9D-9EFC-EB75CAEE2D97

Q32064655-FB9772E6-869A-4326-838A-F425C3396D71

P2860

Q32064655-02E266C6-DB84-4496-B1F2-97B2CC646638

Q32064655-0BD3FB35-8B10-4FD6-A61B-44BC9C61B30B

Q32064655-12F76418-6724-4CB7-A020-C55A46B118F7

Q32064655-1C9E0F63-303E-4493-998E-7E95E37C7824

Q32064655-3431C15B-F13E-4237-BB22-41E4BBBED635

Q32064655-3BE1B3F8-E371-4B04-A2F2-4CAF374CC7A4

Q32064655-3C8180F8-EE05-4BB3-89A8-B8F816CEFB0E

Q32064655-471DE1A5-7735-4781-AC78-635C17371978

Q32064655-599A350C-1445-4FCF-9E26-37AE5F8F08A6

Q32064655-5B8884BF-55F6-4A59-91CC-C326BC65409A

P304

Q32064655-5A8BA5D3-E08A-423B-9DE6-E324A611C2DA

P31

Q32064655-1E660EAC-C86A-478F-96F3-B21E69D90C61

P356

Q32064655-CDF0A6C4-B44C-476A-9BE0-175B0E0A4609

P433

Q32064655-B74CFDC6-A13A-4D0D-94CF-F44D21318B72

P478

Q32064655-33F01581-F91C-4D85-94DB-A2C1D25384F9

P577

Q32064655-D84BA07C-82C4-4A40-AA84-0528572E0E20

P698

Q32064655-BD1BA95C-7530-4A0F-A3AA-9EB68339978F

P921

Q32064655-ADB05166-73B7-4618-9926-6AB7F11FA269

P356

00912700122009728

P1433

The Journal of Clinical Pharmacology

P1476

Inhibition of human cytochrome ...... erse transcriptase inhibitors.

@en

P2093

B W Granda

http://www.w3.org/2001/XMLSchema#string

D J Greenblatt

http://www.w3.org/2001/XMLSchema#string

G M Giancarlo

http://www.w3.org/2001/XMLSchema#string

J P Daily

http://www.w3.org/2001/XMLSchema#string

J S Harmatz

http://www.w3.org/2001/XMLSchema#string

L L von Moltke

http://www.w3.org/2001/XMLSchema#string

R I Shader

http://www.w3.org/2001/XMLSchema#string

S X Duan

http://www.w3.org/2001/XMLSchema#string

P2860

Managing resistance to anti-HIV drugs: an important consideration for effective disease management.

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.

Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine

Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1.

In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.

In vitro and in vivo drug interactions involving human CYP3A.

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.

P304

85-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/00912700122009728

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2001-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11225565

http://www.w3.org/2001/XMLSchema#string

P921